title: [First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis].
abstract: OBJECTIVE
  To evaluate efficacy of intensive modified program NHL-BFM-90 (mNHL-BFM-90) in adult poor-prognosis patients with diffuse large B-cell lymphosarcoma (DLBCL) of the bones and soft tissues.
  
  
  METHODS
  The mNHL-BFM-90 program was used in the treatment of 3 male and 2 female patients aged 17-69 years (median 42 years). Four patients had DLBCL of the bones and one patient--DLBCL of the soft tissues. All the patients had tumors more than 10 cm in size. B-symptoms, a high concentration of lactate dehydrogenase (LDG) were registered in 3 patients. One patient had stage IE by Ann-Arbor, two--stage IIE (involvement of regional lymph nodes), two--stage ME (multiple bone lesions). A total of 4-6 blocks of polychemotherapy according to mNHL-BFM-90 program were performed.
  
  
  RESULTS
  Complete remissions were achieved in all the patients. They had no recurrences after 6 to 20 month (median 13 months) follow-up.
  
  
  CONCLUSIONS
  Positive results of the program mNHL-BFM-90 in poor-prognosis patients with DLBCL of the bones and tissues necessitate further studies of this therapy.
authors.forename: A K
authors.initials: AK
authors.lastname: Morozova
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: A U
authors.initials: AU
authors.lastname: Magomedova
authors.forename: T N
authors.initials: TN
authors.lastname: Obukhova
authors.forename: V E
authors.initials: VE
authors.lastname: Mamonov
authors.forename: E A
authors.initials: EA
authors.lastname: Bariakh
authors.forename: A V
authors.initials: AV
authors.lastname: Gubkin
authors.forename: A I
authors.initials: AI
authors.lastname: Lukina
authors.forename: E A
authors.initials: EA
authors.lastname: Iliushkina
authors.forename: O S
authors.initials: OS
authors.lastname: Fink
authors.forename: T N
authors.initials: TN
authors.lastname: Perestoronina
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D055815:Young Adult
chemical_list: D007770:L-Lactate Dehydrogenase